Literature DB >> 16511389

Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.

Carrie L Byington1, Kent Korgenski, Judy Daly, Krow Ampofo, Andrew Pavia, Edward O Mason.   

Abstract

BACKGROUND: Pediatric pneumococcal parapneumonic empyema (PPE) has become increasingly common. In the last decade, Utah has had one of the highest rates of PPE in the United States, 14/100,000 children, attributed primarily to Streptococcus pneumoniae serotype 1. Our objective was to describe the temporal trends in PPE in Utah before and after the availability of the 7-valent pneumococcal conjugate vaccine (PCV-7).
METHODS: The Intermountain Health Care (IHC) data warehouse was queried for all cases of empyema in children younger than 18 years, defined as International Classification of Diseases, 9th revision, Clinical Modification code 510.9, for the study period March 1996-June 2005. We also retrieved and serotyped all blood and pleural fluid isolates of S. pneumoniae from children younger than 18 years with a diagnosis of PPE at Primary Children's Medical Center (PCMC) between March 1996 and June 2005. The pre-PCV-7 period (PRE) included 57 months (March 1996-December 2000) and the post-PCV-7 period (POST) included 54 months (January 2001-June 2005).
RESULTS: We identified 776 cases of pediatric empyema in the IHC system, and 478 (62%) were managed at PCMC. In the years 1996-2000, we managed a mean of 38 cases of empyema per year compared with 71.5 cases per year between 2001 and 2004 (P = 0.006). At PCMC, there were 295 cases of invasive pneumococcal disease (IPD), and 74 (25%) were PPE. During the PRE period, PPE represented 24 of 137 (17.5%) cases of IPD compared with 50 of 158 (32%) in the POST period (P = 0.008). One-half of the children with PPE required intensive care and 4 died. During the PRE and POST periods, PPE was most often caused by serotype 1 (46 and 34%, respectively), but in the POST period serogroups 3 (20%), and 19A (14%) were also prevalent. PPE in PCV-7-immunized children was caused exclusively by nonvaccine serotypes.
CONCLUSIONS: PPE in the post-PCV-7 era is more common, representing one-third of the IPD in children in UT. PPE is associated with significant morbidity and mortality. Serotype 1 remains the most common cause of PPE, but serotypes 3 and 19A are emerging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511389     DOI: 10.1097/01.inf.0000202137.37642.ab

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  65 in total

1.  Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008.

Authors:  A Fenoll; L Aguilar; M D Vicioso; M J Gimenez; O Robledo; J J Granizo; C Mendez
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Pneumococcal vaccination: time to move on?

Authors:  Marijke Johanna Proesmans
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

3.  Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Yuwei Zhu; Marie R Griffin
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

4.  National hospitalization trends for pediatric pneumonia and associated complications.

Authors:  Grace E Lee; Scott A Lorch; Seth Sheffler-Collins; Matthew P Kronman; Samir S Shah
Journal:  Pediatrics       Date:  2010-07-19       Impact factor: 7.124

5.  Empyema thoracis is still increasing in UK children.

Authors:  David A Spencer; Shaikh Mohammed Iqbal; Asif Hasan; Leslie Hamilton
Journal:  BMJ       Date:  2006-06-03

6.  Management of parapneumonic empyema.

Authors:  Krow Ampofo; Carrie Byington
Journal:  Pediatr Infect Dis J       Date:  2007-05       Impact factor: 2.129

7.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

Review 8.  Clinical practice: treatment of childhood empyema.

Authors:  Marijke Proesmans; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2009-02-24       Impact factor: 3.183

9.  Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah.

Authors:  Carrie L Byington; Kristina G Hulten; Krow Ampofo; Xiaoming Sheng; Andrew T Pavia; Anne J Blaschke; Melinda Pettigrew; Kent Korgenski; Judy Daly; Edward O Mason
Journal:  J Clin Microbiol       Date:  2009-12-16       Impact factor: 5.948

Review 10.  Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine.

Authors:  Inci Yildirim; Kimberly M Shea; Stephen I Pelton
Journal:  Infect Dis Clin North Am       Date:  2015-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.